Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

Cell Death and Differentiation

Volumn 15, Issue 4, 2008, Pages 751-761

  Adams, C ^a   Totpal, K ^a   Lawrence, D ^a   Marsters, S ^a   Pitti, R ^a   Yee, S ^a   Ross, S ^a   Deforge, L ^a   Koeppen, H ^a   Sagolla, M ^a   Compaan, D ^a   Lowman, H ^a   Hymowitz, S ^a   Ashkenazi, A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMAB; CASPASE 8; DEATH RECEPTOR 5; FAS ANTIGEN; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL SURFACE; CLUSTER ANALYSIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIVER CELL; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BINDING SITES, ANTIBODY; CASPASE 8; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPE MAPPING; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR AGGREGATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40949138762     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402306     Document Type: Article

References (50)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J et al Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 22: 598-609.
3. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
4. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-885.
5. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194.
6. Rowinsky EK. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394-9407.
7. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-219.
8. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 57-70.
10. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
11. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001; 92: 57-70.
12. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
13. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003; 13: 115-123.
14. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
15. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-410.
16. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
17. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
18. Igney F, Krammer P. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
19. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
20. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
21. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
22. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
23. Kelley S, Ashkenazi A. Targeting death receptors in cancer with Apo2L/ TRAIL. Curr Opin Pharmacol 2004; 4: 333-339.
24. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 2001; 166 4891-4898.
25. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
26. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and Supplementary Information accompanies the paper on Cell Death. Br J Haematol 2005; 130 501-510.
27. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92: 1430-1441.
28. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces cespase-dependent and caspase-independent cell death. J Biol Chem 2005; 280: 41940-41952.
29. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R et al Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005; 11: 3126-3135.
30. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25: 1390-1395.
31. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell-carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251: 146-157.
32. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-6194.
33. Hymowitz S, Christinger H, Fuh G, Ultsch M , O'Connell M, Kelley R et al. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-571.
34. Hymowitz 8, O'Connell M,Ultsch M, Hurst A, Totpal K, Ashkenazi A et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2/TRAIL. Biochemistry 2000; 39: 633-640.
35. Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Maziere AM et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA 2006; 103:10283-10288.
36. Buchsbaum DJ, Znou T, Lobuglio-AF. TRAIL receptor-targeted therapy. Future Oncol 2006; 2: 493-508.
37. Cha SS, Kim MS Choi YH, Sung BJ, Shin NK, Shin HC et al. 2.8 Å resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11: 253-261.
38. Mongkolsapaya J, Grimes J, Chen N, Xu X, Stuart D, Jones E et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6 1048-1053.
39. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
40. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either allone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2646-2646.
41. Mori E, Thomas M, Motoki K, Na.kazawa K, Tahara T, Tomizuka K et al Human normal hepatocytes are susceptible to apoptosis signal madiated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004; 11: 203-207.
42. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoplosis signaling. J Biol Chem 2005; 280: 2205-2212.
43. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65: 11265-11270.
44. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-1077.
45. Sheridan J, Marsters S, Pitti R, Gumey A, Skubalch K Baldwin D et al Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997 277: 818-821.
46. Marsters S, Sheridan J, Pitti R, Huang A, Skubatch M, Baldwin D et al A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003-1006.
47. Emery JG, McDonnell P, Burke MB, Dean KC, Lyn S, Silverman C et al Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
48. Kunkel TA, Roberts JD, Zakour RA. Rapid and efficient sits-specific mutagenesis without phenotypic selection. Methods Enzymol 1987; 154: 367-382.
49. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab, libraries with a single tramework scaffold. J Mol Biol 2004; 340: 1073-1093.
50. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.